Drugs / SOT102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05525286 | Mar 2022 → Dec 2024 | malignant pancreatic neoplasm | SOTIO Biotech a.s. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-04-12 | SOTIO a.s. | Results SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies sotio.com ↗
The data, which demonstrate that SOT102 has strong potential to eliminate CLDN18.2-expressing tumor cells in a target-specific manner, provide proof of concept for SOT102 as well as SOTIO’s proprietary ADC platform. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOT102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05525286 ↗ |
| Modality | Other / unclassified | “SOT102 is an antibody-drug conjugate (ADC)” NCT05525286 ↗ |
| Route | Intravenous | “via the IV route” NCT05525286 ↗ |
| Target | CLDN18 | “targeting CLDN18.2” NCT05525286 ↗ |